A working monograph library for the mushrooms, mineral complexes, and botanical compounds inside MYKO formulas — each chosen for a specific role and graded against the strength of available evidence.
Filter by what you're working on. Each card opens a full monograph with sourcing, mechanism, and evidence notes.
Hericenones and erinacines are studied for their relationship to NGF signaling, neurite outgrowth, and neuroplasticity pathways. Human research suggests cognitive support with consistent use.
Cordycepin is studied for AMPK-related energy metabolism, ATP production, and fatigue-resilience pathways — supporting the energy demand of cognition and performance.
Fulvic acid may help bind and transport minerals in bioavailable ionic forms while contributing trace minerals and antioxidant activity — the connective tissue of the MYKO system.
Reishi triterpenes and beta-glucans are studied for immune regulation, stress-response support, and calm recovery. Used to ground more activating formulas.
Melanin compounds, beta-glucans, and polyphenols associated with oxidative-stress support and cellular resilience — for formulas where protection and restoration matter.
Polysaccharopeptides studied for immune modulation and gut-microbiome support. Referenced as background research only — not a disease-treatment claim.
Studied for its relationship to 5-HT2A receptor activity, BDNF/TrkB signaling, and cognitive flexibility. MYKO's specific low-dose formulas have not been clinically evaluated.
The rare-species center of EUPHORIA — a lighter, warmer, more emotionally open profile. Understood through the broader serotonergic pathway; character based on emerging observation, not strong clinical evidence.
An optional protocol pairing in low-dose botanical cycling. Involved in NAD/NADP metabolism; can create a skin flush via vasodilation. Protocol tool, not a required ingredient.
A four-tier system adapted from evidence-based medicine — each tier signals how much weight the underlying research carries for a public claim.
Randomized controlled trials, systematic reviews, or meta-analyses in humans. Strongest level for public-facing claims.
Smaller human trials, open-label studies, cohort data, or strong translational evidence. Useful but qualified.
Animal, in-vitro, traditional, or practitioner-supported evidence. Useful for formulation logic, not proof of human outcomes.
Anecdotal, community, or early-stage reports. Useful for hypothesis generation only.
Extract ratios denote how much raw material is concentrated into one unit of extract. A 7:1 ratio means 7 lbs of raw material reduced to 1 lb of extract.
Whole mushroom as harvested — ~85% water. Contains the full spectrum of compounds, but at low concentration.
Water removed via extraction; active compounds concentrated 7–12×. A 200mg extract capsule ≈ 1,400–2,400mg raw equivalent.
You'd need 8–10 capsules of raw powder to match the active load of one extract capsule. Extracts make real dosing practical.
MYKO uses fruiting-body extracts wherever possible — grain-based substrates dilute active compounds with starch. A higher ratio isn't automatically better; what matters is whether the extract preserves the relevant compounds and is tested for purity.
Some compounds are not appropriate for everyone. If any of the following apply to you, consult a qualified healthcare professional first.
This page is educational and does not claim MYKO products diagnose, treat, cure, or prevent any disease.
